ライフサイエンスコーパス: endocarditis

1 rly [100 days to 1 year]) and late (>1 year) endocarditis.

2 ded subjects were of high risk of infectious endocarditis.

3 of progression toward persistent C. burnetii endocarditis.

4 VR), including valve function, thrombus, and endocarditis.

5 symptoms or can progress to chronic, severe endocarditis.

6 7 had acute Q fever and 48 had acute Q fever endocarditis.

7 and 0.88 (0.86-0.91, 78.5%) for all cases of endocarditis.

8 rs; 52 patients (17%) had a prior history of endocarditis.

9 arditis and for the prevention of persistent endocarditis.

10 ved in neurologic complications of infective endocarditis.

11 ococcus aureus, a leading cause of bacterial endocarditis.

12 ation of laboratory testing for diagnosis of endocarditis.

13 netii can cause a life-threatening infective endocarditis.

14 tion and low incidence of stent fracture and endocarditis.

15 17 patients (1.9-fold increase) had definite endocarditis.

16 Infective endocarditis.

17 rom acute fever and fatigue to chronic fatal endocarditis.

18 ations of Streptococcus agalactiae infective endocarditis.

19 e clinical syndromes, such as meningitis and endocarditis.

20 ot meet the CSTE case definition for Q fever endocarditis.

21 were reviewed to identify reports describing endocarditis.

22 lis is a leading cause of subacute infective endocarditis.

23 he contemporary epidemiology and outcomes of endocarditis.

24 terial disease, rheumatic heart disease, and endocarditis.

25 ure perfusion model and a new mouse model of endocarditis.

26 lococcus lugdunensis is an emerging cause of endocarditis.

27 is and in-hospital mortality after infective endocarditis.

28 sociated with an increased risk of infective endocarditis.

29 ike illness that can also present as chronic endocarditis.

30 infections (UTIs), bacteremia, and infective endocarditis.

31 ptococcus mutans and virulence for infective endocarditis.

32 ermease A [BepA]), as important in infective endocarditis.

33 current acute rheumatic fever, and infective endocarditis.

34 iseases, Ninth Revision (ICD-9) diagnosis of endocarditis.

35 ognosis, particularly for infections such as endocarditis.

36 l infections such as bacteremia, sepsis, and endocarditis.

37 s should be tested in blood culture-negative endocarditis.

38 treatment of refractory MSSA bacteremia and endocarditis.

39 (65+/-17 years, 51% females) with infective endocarditis.

40 prophylaxis guidelines on incident infective endocarditis.

41 to 2.287) were independently associated with endocarditis.

42 ed synergistic action in a rat model of MSSA endocarditis.

43 ospitalizations for IDRIs involved infective endocarditis.

44 rium may cause the serious illness infective endocarditis.

45 0.67), bleeding 0.22%/y (95% CI, 0.16-0.32), endocarditis 0.48%/y (95% CI, 0.37-0.62), and 20-year po

46 21.3%, reoperation on the MV 4.6%, infective endocarditis 1.1%, thromboembolism 10.3%, and bleeding 6

47 est, most uninsured, had the highest rate of endocarditis (16%) and hepatitis C (44%).

48 3 to -$1,761), and increased readmission for endocarditis (18.1% vs.

49 patient-years), and 20 (0.7%) had infective endocarditis (3.65/1000 patient-years).

50 e, 34.5 vs 60 years) and more frequently had endocarditis (39% vs 3%).

51 y valve stent fracture (3.4%) and infectious endocarditis (4.3%) were both low.

52 Endocarditis (4.5% versus 2.5%, P=0.037) and aortic diss

53 Among those with peri-procedural endocarditis, 47.9% of patients had a pathogen that was

54 Of 140 case report forms reporting endocarditis, 49 met the confirmed definition and 36 met

55 ences in NSVD (57.8% vs. 54.0%; p = 0.52) or endocarditis (5.9% vs. 5.8%; p = 0.95).

56 ost common infections were bacteremia and/or endocarditis (73.5%), bone and/or joint infections (32.4

57 n 71%, thromboembolism 12%, bleeding 5%, and endocarditis 9%.

58 cus sanguinisis a leading cause of infective endocarditis, a life-threatening infection of the cardio

59 nd receiving services for skin infections or endocarditis (adjusted ORs: HIV, 0.91 [95% CI, 0.87-0.95

60 Data from the multicenter Infectious Endocarditis After TAVR International Registry was used

61 Infective endocarditis after TAVR most frequently occurs during th

62 for peri-procedural, delayed-early, and late endocarditis after TAVR was 2.59, 0.71, and 0.40 events

63 of microorganisms, and outcomes of infective endocarditis after TAVR.

64 s and outcomes of patients who had infective endocarditis after undergoing transcatheter aortic valve

65 era, or between patients with versus without endocarditis (all p > 0.05).

66 2 wk in high-risk patients with SAB without endocarditis and absence of metastatic infection on (18)

67 New cases of endocarditis and aortic dissection were recorded.

68 gurgitation), aortopathy, and complications (endocarditis and aortic dissection).

69 s of Mycobacterium chimaera prosthetic valve endocarditis and disseminated disease were notified in E

70 rtunity for early diagnosis of acute Q fever endocarditis and for the prevention of persistent endoca

71 Infective endocarditis and in-hospital mortality after infective e

72 relapsing infections such as osteomyelitis, endocarditis and infections of implanted devices.

73 valve replacement for incidence of infective endocarditis and infective endocarditis for in-hospital

74 Urosepsis was more common in females; endocarditis and mediastinitis in men.

75 portunistic infections, including infectious endocarditis and otitis media (OM).

76 le reviews the challenges posed by infective endocarditis and outlines current and future strategies

77 tal antibiotic prophylaxis for prevention of endocarditis and prosthetic joint infections.

78 antibiotic prophylaxis for the prevention of endocarditis and prosthetic joint infections.

79 aemia in association with subacute bacterial endocarditis and shunt nephritis.

80 nce, microbiology, and outcomes of infective endocarditis and the effect of changes in national antib

81 mes were crude and standardized incidence of endocarditis and trends in patient characteristics and d

82 : 12 months), 9 patients were diagnosed with endocarditis, and 17 additional patients underwent surgi

83 remia, 13% deep abscesses, 10% pneumonia, 7% endocarditis, and 6% skeletal infections.

84 ortic aneurysm, peripheral arterial disease, endocarditis, and all other cardiovascular diseases comb

85 antibiotics possessing greater efficacy for endocarditis, and also little or no activity against tho

86 c lung disease, chronic heart failure, prior endocarditis, and degenerative valve disease; and had hi

87 , namely bacteremia, nonbacterial thrombotic endocarditis, and healthy controls.

88 TV dysfunction, endocarditis, and leaflet thrombosis were uncommon after

89 and undulant fever, debilitating arthritis, endocarditis, and meningitis in humans.

90 ans of survival, reinterventions, infectious endocarditis, and performance of the valves.

91 lacement in patients with subacute bacterial endocarditis, and posthumous donation of sperm.

92 thout AIDS, the viral hepatitides, infective endocarditis, and skin and soft-tissue infections.

93 Patients with congenital heart disease, with endocarditis, and undergoing concomitant cardiac operati

94 stroke, aortic dissection, valve thrombosis, endocarditis, and urgent cardiac intervention.

95 A mutant lacking endocarditis- and biofilm-associated pili (Ebp) exhibite

96 or more of the following: pocket infection; endocarditis; and bloodstream infection.

97 ersus SAVR for major vascular complications, endocarditis, aortic valve re-intervention, and New York

98 Prospective analyses of culture-negative endocarditis are needed to better assess the clinical sp

99 The challenges posed by infective endocarditis are significant.

100 rdiac imaging in native and prosthetic valve endocarditis, as well as cardiac implantable electronic

101 increases in overdoses, viral hepatitis, and endocarditis associated with drug use have been well-doc

102 ansferase system (PTS) permease (biofilm and endocarditis-associated permease A [BepA]), as important

103 In blood culture-negative endocarditis (BCNE), 22% of cases remain undiagnosed des

104 ed as a diagnostic tool for prosthetic valve endocarditis, but its specificity is limited by uptake o

105 associated sternal osteomyelitis, infective endocarditis) caused by Staphylococcus aureus.

106 Hospitalizations for endocarditis, central nervous system/spine infections, o

107 reased the risk of EE in candidemia included endocarditis, cirrhosis, diabetes with chronic complicat

108 ical and epidemiological features of Q fever endocarditis collected through passive surveillance in t

109 residents with claims for skin infections or endocarditis, commonly associated with injection drug us

110 causes more-aggressive infections, including endocarditis, compared with other coagulase-negative sta

111 aging in the assessment of local and distant endocarditis complications such as pericardial sequelae,

112 Some cases of apparent Q fever endocarditis could not be classified by CSTE laboratory

113 ients with health care-associated nosocomial endocarditis decreased (from 17.7% to 15.3%; APC, -1.0%;

114 the proportion of patients with native-valve endocarditis decreased (from 74.5% to 68.4%; APC, -0.7%;

115 ntified a new clinical entity, acute Q fever endocarditis, defined as valvular lesion potentially cau

116 ly associated with all-cause mortality after endocarditis diagnosis (hazard ratio, 4.4 [95% CI, 3.42-

117 microbiologic and pathological algorithm for endocarditis diagnosis.

118 VR group, and the estimated survival free of endocarditis did not differ significantly between groups

119 The incidence of oral streptococcal endocarditis did not increase (unadjusted: APC, -0.1%; 9

120 imates of skin and soft-tissue infection and endocarditis disease burden with related IDU or substanc

121 Drug use-associated infective endocarditis (DUA-IE) is increasing as a result of the o

122 apture data on drug use-associated infective endocarditis (DUA-IE).

123 -year-old German woman with prosthetic valve endocarditis due to Bartonella washoensis The infecting

124 mbined with antibiotics against experimental endocarditis (EE) due to Pseudomonas aeruginosa, an arch

125 Enterococcal endocarditis (EE) is a growing entity in Western countri

126 Among patients with early endocarditis, Enterococcus species were the most frequen

127 alizations for serious infections (infective endocarditis, epidural abscess, septic arthritis, and os

128 erest was all hospitalizations for infective endocarditis, epidural abscess, septic arthritis, or ost

129 0.4%-19.2%) of patients during the infective endocarditis episode.

130 ore, a useful adjunct modality for assessing endocarditis, especially in the challenging scenarios of

131 The final diagnosis of CIED infection by the endocarditis expert team was based on the modified Duke-

132 ence of infective endocarditis and infective endocarditis for in-hospital mortality.

133 raded from possible endocarditis to definite endocarditis for only 4 cases (0.8%).

134 ch, all patients hospitalized with infective endocarditis from 1990 to 2014 were identified and linke

135 rst-line modalities for clinically suspected endocarditis given their ability to detect vegetation an

136 igher microglial activation in the infective endocarditis group (n = 11/23, 48%), when compared with

137 erns observed in the nonbacterial thrombotic endocarditis group were similar to those observed in the

138 In the infective endocarditis group, MRI revealed at least one cerebral l

139 In the infective endocarditis group, neuropathology revealed brain infarc

140 e similar to those observed in the infective endocarditis group.

141 1, 9%; p = 0.03) and nonbacterial thrombotic endocarditis groups (n = 0/7, 0%; p = 0.02).

142 Patients who developed endocarditis had high rates of in-hospital mortality and

143 No patients with culture-negative endocarditis had organisms identified by mNGS.

144 Eight patients with endocarditis had phase I immunoglobulin G antibody titer

145 guidelines, the crude incidence of infective endocarditis has remained stable.

146 laxis and treatment guidelines for infective endocarditis have changed substantially over the past de

147 adjusted incidence and outcomes of infective endocarditis hospitalizations.

148 atients hospitalized with a first episode of endocarditis identified from mandatory state databases i

149 Injection drug use-associated infective endocarditis (IDU-IE) is rising and valve surgery is fre

150 with injection drug use-associated infective endocarditis (IDU-IE), against medical advice (AMA) disc

151 dental procedures in patients with infective endocarditis (IE) according to whether the IE-causing mi

152 and national burden estimates for infective endocarditis (IE) and skin and soft-tissue infections re

153 ocardiography in the evaluation of infective endocarditis (IE) and surgical planning.

154 prophylaxis for the prevention of infective endocarditis (IE) for only the highest-risk patients.

155 ising rates of hospitalization for infective endocarditis (IE) have been increasingly tied to rising

156 eople who inject drugs (PWID) with infective endocarditis (IE) have often been retrospective, had a s

157 eople who inject drugs (PWID) with infective endocarditis (IE) have often been retrospective, have ha

158 of all residents hospitalized for infective endocarditis (IE) in an acute care hospital from 1 Janua

159 of all residents hospitalized for infective endocarditis (IE) in an acute care hospital.

160 n-based epidemiological changes in infective endocarditis (IE) in Europe.

161 eful diagnostic tool for suspected infective endocarditis (IE) in patients with prosthetic valves or

162 s, 9thRevision diagnosis codes for infective endocarditis (IE) in the National Inpatient Sample, a re

163 Infective endocarditis (IE) is a complex disease with cardiac invo

164 ating the portal of entry (POE) of infective endocarditis (IE) is important, but published research o

165 cted heart valves of patients with infective endocarditis (IE) is influenced by pre-operative antibio

166 Infective endocarditis (IE) is the most feared complication of Sta

167 Infective endocarditis (IE) often requires surgical intervention.

168 exist about the characteristics of infective endocarditis (IE) post-transcatheter aortic valve replac

169 Background Infective endocarditis (IE) remains a difficult to diagnose condit

170 phylaxis (AP) for those at risk of infective endocarditis (IE) undergoing dental procedures in the Un

171 commonly used for the diagnosis of infective endocarditis (IE), but its prognostic value remains unkn

172 e of bacterial infections, such as infective endocarditis (IE), have been reported in conjunction wit

173 is an important etiologic agent of infective endocarditis (IE), particularly in people with predispos

174 In the management of infective endocarditis (IE), the presence of extracardiac complica

175 nt increases in infections such as infective endocarditis (IE), which is tied to injection behaviors.

176 Streptococci frequently cause infective endocarditis (IE), yet the prevalence of IE in patients

177 n the evaluation and management of infective endocarditis (IE)-a condition with high morbidity and mo

178 as proven efficacious for treating infective endocarditis (IE).

179 s the third most frequent cause of infective endocarditis (IE).

180 hagic stroke (HS) in patients with infective endocarditis (IE).

181 VR) are considered at high risk of infective endocarditis (IE).

182 and important agents of bacterial infective endocarditis (IE).

183 oke (IS) during the acute phase of infective endocarditis (IE).

184 isk of deleterious sequelae due to infective endocarditis (IE).

185 particularly more common among patients with endocarditis, immunocompromising comorbidities, and drug

186 bacteremia in 52%, osteomyelitis in 10%, and endocarditis in 10%.

187 hii is demonstrated as causing archaemia and endocarditis in febrile patients who are coinfected by b

188 p. have been found to cause culture-negative endocarditis in humans.

189 gen, as well as a leading cause of infective endocarditis in humans.

190 c tamponade (1B), valvular dysfunction (1C), endocarditis in native (2C) or mechanical valves (1B), g

191 e clinical spectrum and magnitude of Q fever endocarditis in the United States.

192 here are few descriptive analyses of Q fever endocarditis in the United States.

193 in the incidence and etiologies of infective endocarditis in the United States.

194 phylococcus epidermidis pacemaker-associated endocarditis, in a patient who developed a break-through

195 ts with health care-associated nonnosocomial endocarditis increased (from 32.1% to 35.9%; APC, 0.8%;

196 onic Q fever develops, mostly manifesting as endocarditis, infected aneurysms, or infected vascular p

197 ylococcus aureus bacteremia, and right-sided endocarditis infections associated with S. aureus, inclu

198 of nosocomial infections, of which infective endocarditis is associated with substantial mortality.

199 interaction in the pathogenesis of infective endocarditis is attachment of the organisms to host plat

200 Coxiella burnetii endocarditis is considered to be a late complication of

201 Infective endocarditis is defined by a focus of infection within t

202 eople who inject drugs (PWID) with infective endocarditis is good, long-term survival is poor due to

203 Infective endocarditis is life-threatening; identification of the

204 valve surgery and in-hospital mortality for endocarditis is not known.

205 ar structures were observed on all infective endocarditis isolates examined, suggesting that this dis

206 ased approach for the treatment of infective endocarditis, leading to a strong reduction of mortality

207 ring cardiac surgery of left-sided infective endocarditis (LSIE) helps to guide antibiotic treatment.

208 Infective endocarditis may affect patients after transcatheter aor

209 Infective endocarditis may require valve surgery, but surgical tre

210 Among 75829 patients with first episodes of endocarditis (mean [SD] age, 62.3 [18.9] years; 59.1% ma

211 Endocarditis, meningitis, prostatitis, osteomyelitis, in

212 also resulted in attenuation in an infective endocarditis model (P = 0.0088).

213 mapping (M-TraM) approach to evaluate a rat endocarditis model and identified a gene, originally ann

214 and oxacillin persistence in an experimental endocarditis model in vivo.

215 Neurologic lesions observed in the infective endocarditis model were compared with three other condit

216 reover, with the use of the rabbit infective endocarditis model, we demonstrate that the disulfide bo

217 SA300 JE2 pathogenesis using a rat infective endocarditis model.

218 of the nox mutant was attenuated in a rabbit endocarditis model.

219 (Northwest), aortic aneurysm (Midwest), and endocarditis (Mountain West and Alaska).

220 serious infections, including osteomyelitis, endocarditis, necrotizing pneumonia and sepsis(1).

221 with those of 3,308 cases of nonenterococcal endocarditis (NEE).

222 ic valve endocarditis (PVE) and native valve endocarditis (NVE).

223 FDG-PET/CT for the diagnosis of native valve endocarditis (NVE).

224 During follow-up of 14,832 patient-years, endocarditis occurred in 149 patients.

225 A total of 250 cases of infective endocarditis occurred in 20006 patients after TAVR (inci

226 is or other adverse outcomes after TTVR, and endocarditis occurred with similar frequency in differen

227 Infective endocarditis occurs worldwide, and is defined by infecti

228 independently associated with acute Q fever endocarditis (odds ratio [OR], 2.7 [95% confidence inter

229 was used successfully to salvage 11 cases (6 endocarditis) of persistent methicillin-susceptible Stap

230 Patients with infective endocarditis on the left side of the heart are typically

231 igned 400 adults in stable condition who had endocarditis on the left side of the heart caused by str

232 In patients with endocarditis on the left side of the heart who were in s

233 n age of the 5 male patients, diagnosed with endocarditis or aortic graft infection, was 57.8 years.

234 ior endocarditis were not at higher risk for endocarditis or other adverse outcomes after TTVR, and e

235 Candida endocarditis (OR, 1.84), cirrhosis (OR, 1.93), diabetes

236 Acute Q fever endocarditis (OR, 5.2 [95% CI, 2.6-10.5]; P < .001) and

237 al implants without evidence for thrombosis, endocarditis, or excessive calcification.

238 is was not a risk factor for reintervention, endocarditis, or valve thrombosis, and there was no diff

239 prevention, early diagnosis and treatment of endocarditis, oral anticoagulation for atrial fibrillati

240 atients diagnosed with bacteremia or sepsis, endocarditis, osteomyelitis or septic arthritis, and ski

241 atients with a substance use diagnosis code, endocarditis, osteomyelitis, sepsis, and SSTVI hospitali

242 Endocarditis, osteomyelitis, sepsis, and SSTVI hospitali

243 likely to demonstrate BEE in the presence of endocarditis (P < 0.001), bacterial meningitis (P < 0.00

244 ticularly in the setting of prosthetic valve endocarditis, paravalvular extension of infection, and c

245 tonella quintana; it was also found to cause endocarditis, peliosis hepatis, and bacillary angiomatos

246 ger than 1 year; Maori or Pacific ethnicity; endocarditis, pneumonia, or sepsis; and receiving no tre

247 genic strains causing meningitis, arthritis, endocarditis, polyserositis, and septicemia.

248 ations raised at the horizon as arrhythmias, endocarditis, pulmonary hypertension, and heart failure,

249 alue of (18)F-FDG PET/CT in prosthetic valve endocarditis (PVE) and native valve endocarditis (NVE).

250 Prosthetic valve endocarditis (PVE) is a rare but critical mechanism of v

251 In non-operated prosthetic valve endocarditis (PVE), long term outcome is largely unknown

252 In nonoperated prosthetic valve endocarditis (PVE), long-term outcome is largely unknown

253 ps of patients with NVE and prosthetic valve endocarditis (PVE)/ascending aortic prosthesis infection

254 the cerebral lesion spectrum in an infective endocarditis rat model.

255 This original model of infective endocarditis recapitulates the neurologic lesion spectru

256 espite improvements in management, infective endocarditis remains associated with high mortality and

257 outcomes of Staphylococcus aureus infective endocarditis (SAIE) remains controversial.

258 rt the younger demographic; however, Candida endocarditis seen among approximately 40% underscores th

259 soft-tissue, and venous infections (SSTVIs), endocarditis, sepsis, and osteomyelitis.

260 Given the increased readmission for endocarditis, septicemia, and drug abuse, IDU-IE present

261 ings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and

262 s could provide a rich source of targets for endocarditis-specific antibiotics possessing greater eff

263 at the oral colonizer and cause of infective endocarditis Streptococcus oralis subsp. dentisani displ

264 RHD, RHD complication rates (heart failure, endocarditis, stroke, and atrial fibrillation), and mort

265 cology (n=26), suspicion of prosthetic valve endocarditis subsequently excluded (n=17), and history o

266 emphasize the need for the functioning of an endocarditis team, including cardiac surgeons, cardiolog

267 of a multidisciplinary heart valve team, the endocarditis team, underlining the importance of cardiac

268 to the Duke modified criteria, validated by endocarditis teams.

269 e cases, Q fever becomes chronic, leading to endocarditis that can be life threatening.

270 nosis of device-related and prosthetic valve endocarditis, that addition has not been incorporated in

271 In Staphylococcus aureus-caused endocarditis, the pathogen secretes staphylocoagulase (S

272 vention, and valve-related adverse outcomes (endocarditis, thrombosis, or significant dysfunction) we

273 ic classification was upgraded from possible endocarditis to definite endocarditis for only 4 cases (

274 mly assigned 121 patients with S. aureus BSI/endocarditis to receive a single dose of exebacase or pl

275 ex test, (b) data were provided as infective endocarditis valvular complications (classified as absce

276 ft main stenosis with unstable angina, acute endocarditis, valvular regurgitation with impending hear

277 st time in any bacterium to be essential for endocarditis virulence.

278 The annualized incidence of infective endocarditis was 1.6% in the Melody group and 0.5% in th

279 Endocarditis was 10-fold more frequent among iGAS patien

280 Median time from TAVR to infective endocarditis was 5.3 months (interquartile range [IQR],

281 Infective endocarditis was classified into early (peri-procedural

282 ee of valve replacement because of infective endocarditis was comparable between both groups (Melody,

283 Endocarditis was diagnosed in 8 patients 2 to 29 months

284 Definite endocarditis was diagnosed in 90 patients, resulting in

285 Prior endocarditis was not a risk factor for reintervention, e

286 Health care-associated infective endocarditis was present in 52.8% (95% CI, 46.6%-59.0%)

287 re risk factors for mortality, whereas prior endocarditis was protective and persistent bacteremia co

288 overall standardized incidence of infective endocarditis was stable from 1998 through 2013, with cha

289 Endocarditis was the most common presentation (n = 11).

290 was most common with 348 cases (32.4%), and endocarditis was uncommon with 30 cases (2.8%).

291 Younger age and endocarditis were also associated with PDD.

292 case-control matched analysis, patients with endocarditis were at increased risk of mortality (hazard

293 Patients with aortic dissection and active endocarditis were excluded.

294 Patients with prior endocarditis were not at higher risk for endocarditis or

295 tients, all diagnosed with infectious mitral endocarditis, were diagnosed by microscopy, PCR-based de

296 s to deep-seated invasive infections such as endocarditis, which is on the rise among young adults ow

297 dy, in this instance, treating or preventing endocarditis while leaving the oral microbiome intact.

298 l, freedom of reinterventions, and infective endocarditis with or without the need of replacement of

299 ing FDG PET/CT in suspected prosthetic valve endocarditis, with specific attention to uptake pattern.

300 dentified a valvular lesion of acute Q fever endocarditis without underlying valvulopathy.